Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Rating) has earned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $53.43.
A number of research firms recently issued reports on AGIO. SVB Leerink lifted their target price on Agios Pharmaceuticals from $33.00 to $37.00 and gave the company an “outperform” rating in a research report on Friday, August 5th. The Goldman Sachs Group raised Agios Pharmaceuticals from a “sell” rating to a “neutral” rating and lifted their target price for the company from $17.00 to $32.00 in a research report on Thursday, November 17th. Finally, StockNews.com began coverage on Agios Pharmaceuticals in a research report on Wednesday, October 12th. They issued a “sell” rating on the stock.
Hedge Funds Weigh In On Agios Pharmaceuticals
A number of institutional investors have recently bought and sold shares of AGIO. Armistice Capital LLC acquired a new position in Agios Pharmaceuticals during the third quarter worth approximately $54,411,000. Fisher Asset Management LLC acquired a new position in Agios Pharmaceuticals during the third quarter worth approximately $23,738,000. Victory Capital Management Inc. acquired a new position in Agios Pharmaceuticals during the third quarter worth approximately $21,982,000. UBS Asset Management Americas Inc. grew its position in shares of Agios Pharmaceuticals by 635.7% in the second quarter. UBS Asset Management Americas Inc. now owns 476,013 shares of the biopharmaceutical company’s stock valued at $10,553,000 after purchasing an additional 411,312 shares during the last quarter. Finally, Federated Hermes Inc. acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $8,362,000.
Agios Pharmaceuticals Price Performance
Agios Pharmaceuticals (NASDAQ:AGIO – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.49) EPS for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.22. The firm had revenue of $3.52 million during the quarter, compared to the consensus estimate of $5.24 million. During the same quarter last year, the firm earned ($1.48) earnings per share. On average, equities analysts expect that Agios Pharmaceuticals will post -6.34 EPS for the current year.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.
- Get a free copy of the StockNews.com research report on Agios Pharmaceuticals (AGIO)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.